Clinical Trials Browser

INDUSTRY × Glioma × Imatinib Mesylate × Clear all

NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2 Terminated

231 enrolled 12 charts

Glioblastoma, Glioma